Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies
The results come amid the rollout of Biogen and Eisai’s Leqembi, the first drug found to slow the progression of Alzheimer’s to win FDA approval.
More Stories
Dr. Steinbrech Releases Annual Top 10 Celebrity Faces in Male Plastic Surgery for 2024
New York, NY - December 6, 2024 - Dr. Steinbrech, a leading plastic surgeon renowned for his expertise in male...
At the Pinnacle of Artistry: Danilo Bonazza, a Global Leader in Mosaic Art
From the ancient mosaics of Ravenna, Italy, to the modern landscapes of New Jersey, Danilo Bonazza has cemented his place...
Hard Rock chairman opens the door to a FanDuel or DraftKings partnership in Florida
Hard Rock has the monopoly on sports betting in Florida, winning the exclusive tribal gaming compact after a battle against...
Slotmaker Aristocrat works to protect its IP while moving to a digital future
Aristocrat Gaming CEO Hector Fernandez told CNBC that digital opportunities and protecting intellectual property are key to the company's future.
BetMGM wagers that new technology, football can lead to a resurgence
BetMGM is trying to regain lost ground in both sports gambling and online casino games.
Spirit Halloween to open 10 new ‘Spirit Christmas’ stores catering to holiday shoppers
Spirit Halloween's usual trick-or-treat and go is no longer, as the company announced it will open "Spirit Christmas" locations through...